Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 18/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 13/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 11/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5115604 | 1.00 | CHRM1 (0.56) | CHRM1CHRM2CHRM4NAMPT | |
| SCHEMBL4868636 | 1.00 | CHRM1 (0.56) | CHRM1CHRM2CHRM4NAMPT | |
| SCHEMBL4870913 | 0.85 | CHRM1 (0.53) | CHRM1CHRM2CHRM4NAMPT | |
| SCHEMBL4868987 | 0.85 | CHRM1 (0.53) | CHRM1CHRM2CHRM4NAMPT | |
| SCHEMBL4868985 | 0.85 | CHRM1 (0.53) | CHRM1CHRM2CHRM4NAMPT | |
| SCHEMBL2113915 | 0.80 | CHRM1 (0.35) | CHRM1CHRM2CHRM4NAMPT | |
| SCHEMBL4651411 | 0.73 | NR1H2 (0.41) | CHRM1CHRM2CHRM4 | |
| SCHEMBL5121326 | 0.73 | NR1H2 (0.41) | CHRM1CHRM2CHRM4 | |
| SCHEMBL4651408 | 0.73 | NR1H2 (0.41) | CHRM1CHRM2CHRM4 | |
| SCHEMBL2113831 | 0.73 | NR1H2 (0.41) | CHRM1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608617-B1 | MUSCARINIC AGONISTS | LILLY CO ELI (US) | 2013-01-09 | — | — | EP | disclosed |
| US-7378447-B2 | Muscarinic agonists | ELI LILLY AND COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20060178438-A1 | Muscarinic agonists | ELI LILLY AND COMPANY (IN) | 2006-08-10 | — | — | US | disclosed |
| US-20060154922-A1 | Muscarinic agonists | ELILILLY AND COMPANY (US) | 2006-07-13 | — | — | US | disclosed |
| EP-1608619-A1 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004094382-A1 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154922-A1 | Muscarinic agonists | CHRM3, CHRM1, CHRM5 | CHRM1 2/4885CHRM2 4/4885CHRM4 5/4885 |
| US-20060178438-A1 | Muscarinic agonists | CHRM3, CHRM1, CHRM5 | CHRM1 2/4885CHRM2 4/4885CHRM4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.